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ABSTRACT 
 
MODULATION OF INTERLEUKIN-17 BY TUMOR NECROSIS FACTOR- 
ALPHA DURING THE IMMUNE RESPONSE TO BORRELIA BURGDORFERI 
 
by 
 
Velinka Medić 
 
The University of Wisconsin-Milwaukee, 2013 
Under the Supervision of Professor Dean Nardelli 
 
 
Arthritis is one of the main complications of late-stage Lyme borreliosis. Cytokines 
play an important role in the persistent inflammation that is elicited by the causative 
agent of disease, Borrelia burgdorferi. Tumor necrosis factor alpha (TNF-α) is a 
pro-inflammatory cytokine that is induced by B. burgdorferi and that has been 
implicated in development of arthritis. However, in a mouse model of Lyme 
arthritis, treatment with anti-TNF-α antibody increased the severity of disease. By 
contrast, injection of recombinant TNF-α ameliorated arthritis in this model. These 
findings suggested that other factors might be involved during the development of 
Lyme arthritis. One possible factor may be interleukin-17 (IL-17), a pro-
inflammatory cytokine mainly produced by T helper 17 cells. IL-17 has been 
implicated in the development of Lyme arthritis. Treatment with anti-IL-17 
antibodies reduces the inflammatory outcome in animal models of disease. 
However, it is not known how TNF-α affects the response of IL-17 to B. burgdorferi. 
The hypothesis of this thesis is that TNF-α will regulate the immune response to 
B. burgdorferi infection by decreasing IL-17 production. Modulation of IL-17 during 
the immune response to B. burgdorferi was analyzed in wild-type and interleukin-
10 (IL-10)-deficient mice treated with anti-TNF-α antibodies. We found that anti-
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TNF-α antibody treatment increased paw inflammation in both wild-type and IL-10 
deficient mice. In addition, cell cultures from B. burgdorferi-infected, wild-type mice 
treated with anti-TNF-α antibodies typically produced a greater amount of IL-17 
than untreated controls, reasoning that TNF-α decreases IL-17 levels following 
infection. Additional treatment of anti-TNF-α antibody-treated mice with anti-IL-17 
antibodies lessened the severity of paw swelling. Our results indicate that TNF-α 
can play a protective role during the immune response to B. burgdorferi infection 
by restraining the production of IL-17. 
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CHAPTER 1: INTRODUCTION 
I. Lyme Borreliosis 
Zoonotic pathogens have become a threat to human health, despite increased 
awareness and surveillance. The most common tick-borne disease in the United 
States is Lyme borreliosis (Centers for Disease Control and Prevention [CDC]), a 
multi-symptom disease caused by excessive inflammation elicited by Borrelia 
burgdorferi, the pathogenic spirochete. The number of cases of Lyme borreliosis 
has continued to increase annually, with 30,000 reported cases in 2012 (CDC). 
However, in 2013 it was reported that the actual incidence of disease is 10 times 
higher than reported cases, reaching 300,000 per year (CDC). Lyme borreliosis is 
endemic to the East Coast and Great Lakes regions and northern California. This 
geographic pattern, which is expanding, is a result of the combined presence of 
suitable tick vectors and prevalence of infected ticks and animal reservoirs. 
 
B. burgdorferi sensu lato is a complex of 19 genospecies (Rudenko et al., 2011). 
Some of these species are pathogens that cause the development of Lyme 
borreliosis. These pathogenic strains have different geographic ranges and cause 
different disease manifestations. For example, B. burgdorferi sensu stricto is 
responsible for causing Lyme borreliosis in the United States. This species is well 
known for inducing the development of Lyme arthritis in later-stage infection. By 
contrast, B. garinii and B. afzelii are responsible for causing Lyme borreliosis in 
Europe, and, in later stages of disease, typically cause more severe effects of the 
skin and neurological system than B. burgdorferi. These pathogens are deficient 
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in the genes necessary for synthesis of amino acids and fatty acids (Aguero-
Rosenfeld et al., 2005), and, therefore, depend on host cells and tissues and 
immune evasion for survival.  
 
The progression of Lyme borreliosis is often divided into three stages: early 
localized disease, early disseminated disease, and late disease (Steere et al., 
1989). The main clinical manifestation of early disease that is caused by B. 
burgdorferi is a bull’s eye-shaped rash called erythema migrans (EM). EM is 
present in about 70% of cases of infection (Bacon et al., 2008) and, in endemic 
areas, it is considered to be diagnostic (Aguero-Rosenfeld et al., 2005; Wormser 
et al., 2006). EM develops at the site of the tick bite approximately 7 to 14 days 
after infection and usually is accompanied by non-specific, flu-like symptoms 
(O’Connor, 2010). In early disseminated disease, in which B. burgdorferi 
organisms migrate from the skin throughout the body, multiple EM lesions can be 
present, as well as cranial nerve palsy, meningitis, and, rarely, carditis. During this 
stage, fever, fatigue, and headache are also common. The most commonly 
manifested complication of late disease in the United States is arthritis, but 
neurological symptoms such as mood and memory disorders, fatigue, and nerve 
pain may also be observed. By contrast, encephalomyelitis and acrodermatitis 
chronica atrophicans (a skin rash that can lead to skin atrophy and 
polyneuropathy) are common late symptoms of Lyme borreliosis in Europe (Stanek 
et al., 1996), which is a result of infection with pathogenic species other than B. 
burgdorferi, such as B. afzelii and B. garinii. 
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II. Transmission and Dissemination of B. burgdorferi 
Complex interactions between the microbes, vectors, and animal reservoirs lead 
to transmission of B. burgdorferi. The transmission of B. burgdorferi to humans 
depends on the infected deer tick Ixodes scapularis, which is found in the eastern 
and midwestern parts of United States, and I. pacificus, which is found on the 
Pacific coast. In order to understand the transmission of B. burgdorferi, it is 
important to describe the life cycle of I. scapularis. The life cycle of the tick ranges 
from two to four years, and it is divided into four stages: egg, larva, nymph, and 
adult. When I. scapularis ticks hatch, they are free of bacteria. At the first feeding 
on an infected animal reservoir, B. burgdorferi are transmitted into the larvae. After 
molting to the nymph stage, infected I. scapularis feed on another animal reservoir 
and transmit the bacteria to them, which sustains the presence of the bacteria in 
the environment. During the nymph stage, I. scapularis may also feed on humans, 
transmitting the bacteria to them. It has been suggested that humans are 
accidental or “dead-end” hosts (Radolf et al., 2012). Ticks feed on white-footed 
mice, which are considered the main animal reservoir (Mather et al., 1989), and 
deer, which are less competent reservoirs for B. burgdorferi (Telford et al., 1988). 
Other animal reservoirs include squirrels, hares, and various other small 
mammals, as well as birds and lizards (Halperin, 2011). In addition, seasons that 
correspond to the tick life cycle are also important in the transmission of Lyme 
borreliosis. Summer months are when larvae hatch and feed on infected animal 
reservoirs, as well as when nymphs also feed. In these months, there is an 
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increase in the number of reported Lyme borreliosis cases (Bacon et al., 2008). 
Overall, the prevalence of Lyme borreliosis is dependent on a combination of the 
feeding habits of these ticks, the proportion of ticks infected with B. burgdorferi, 
and the presence of animal reservoirs. 
 
The effects of host and tick factors on B. burgdorferi are especially important in 
transmission of the spirochete. There is a change in expression of various outer-
surface proteins (Osp) of B. burgdorferi, mainly OspA and OspC, during the tick 
feedings. In the infected, but unfed, tick, bacteria are contained in the midgut. 
OspA levels are upregulated during colonization of tick midgut, and it has been 
established that OspA plays a role in adhesion to the epithelial cells of ticks by 
binding to a protein named “tick receptor for OspA” (TROSPA) (Pal et al., 2004). 
During feeding, there is a downregulation of OspA, causing detachment of B. 
burgdorferi from TROSPA and migration to the salivary gland. Concomitantly, 
there is an upregulation of OspC, which can bind tick salivary protein 15 (Salp15) 
(Ramamoorthi et al., 2005). It has been demonstrated that Salp15 is needed for B. 
burgdorferi infection. It inhibits CD4+ T cell activation, and its attachment to the 
bacteria allows dissemination into the mammalian host (Samuels, 2010).   
 
After infection with B. burgdorferi, the spirochetes disseminate from the skin into 
the blood and various organs. To enter specific organs, they have to evade host 
defenses and induce the breakdown of extracellular matrix (ECM) components of 
tissues. Other Osp proteins that are produced by the bacteria ensure successful 
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infection and survival in the hosts. When B. burgdorferi enters the mammalian 
host, it disseminates and survives by evading the immune response. OspEF-
related proteins (Erps) bind to complement factor H and complement factor H-like 
1 protein (FHL-1) to inhibit the activity of the alternative complement pathway 
(Antonara et al., 2011). In addition, B. burgdorferi does not produce secreted 
proteases. Instead, it has to rely on inducing host factors that result in tissue 
destruction and dissemination into tissues. For example, B. burgdorferi induces 
production of plasminogen and matrix metalloproteinase-9 (MMP-9), which cause 
ECM degradation (Heilpern et al., 2009). Similarly, adhesion molecules, including 
outer-membrane surface proteins (OMPs), integrin binding protein p66 (Coburn et 
al., 1999), the fibronectin binding protein Bbk32 (Probert and Johnson, 1998), and 
decorin-binding proteins A and B (Hagman et al., 1998), have been shown to aid 
in dissemination within the host, particularly to sites of abundant connective tissue. 
Collectively, these findings demonstrate that different bacterial, tick, and host 
factors for are responsible for successful transmission, establishment of infection, 
and dissemination. 
 
III. Diagnosis and Treatment of Lyme Borreliosis 
The diagnosis of Lyme borreliosis is dependent on a combination of laboratory 
testing and observing clinical manifestations. The CDC requires confirmed cases 
of Lyme borreliosis to meet the following criteria: physician-confirmed EM, or 
positive serological testing with manifestations of cardiac, neurological, or arthritic 
symptoms (CDC). Aside from EM, the clinical manifestations are not specific. 
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However, diagnosis based on EM alone is often difficult. EM does not develop in 
every infected patient, and EM may occasionally be confused with rash, eczema, 
and insect bites (Puius and Kalish, 2007). In addition, EM lesions can be located 
on a part of the body that is difficult to observe, and the rash can be obscured by 
certain skin tones and the presence of hair. As a result, diagnosis of Lyme 
borreliosis only on the basis of observing clinical symptoms can be difficult. 
However, observing EM in an endemic area is often sufficient for a positive 
diagnosis. 
 
Additionally, serological testing is frequently used to diagnose Lyme borreliosis. A 
two-step process is used for laboratory diagnosis: a screening enzyme-linked 
immunosorbent assay (ELISA), followed by a confirmatory Western blot. One 
major disadvantage of this approach is an inability to distinguish between current 
and past infection, since patients can be seropositive for years (Marques, 2010). 
Similarly, detection of B. burgdorferi-specific antibodies in the early stage of 
disease can be challenging, since the sensitivity and specificity of serological 
testing are inadequate at that stage (Shapiro and Gerber, 2000). Furthermore, 
cross-reactive antibodies from other spirochetal infections such as syphilis, 
relapsing fever, or leptospirosis, or from autoimmune diseases such as systemic 
lupus erythematosus, can yield false positives. These issues demonstrate the 
complexity of diagnosing Lyme borreliosis and the need for better diagnostic 
markers.  
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In 2006, the Infectious Diseases Society of America updated the stage-dependent 
guidelines for treatment of Lyme disease (Wormser et al., 2006). For adults at an 
early stage of Lyme disease with no neurological complications, doxycycline, 
amoxicillin, or cefuroxime axetil are recommended for 10-21 days. During the late 
stage of Lyme disease, patients with Lyme arthritis can be treated with the same 
antibiotics, but administered for 28 days. If arthritis is not resolved by the end of 
the first treatment, a second dose of antibiotics is administered for another 4 weeks 
(Shapiro and Gerber, 2000; Wormser et al., 2006).  
 
However, some patients can still present with arthritic symptoms even after a 
second dose of antibiotics. At this point, non-steroidal anti-inflammatory agents 
and corticosteroids are used to counter the high levels of pro-inflammatory 
cytokines found in patients (Shin et al., 2007). In addition, disease-modifying anti-
rheumatic drugs may be used to combat synovial destruction. 
 
There is an ongoing debate in the field of Lyme arthritis research as to whether 
patients treated with several doses of antibiotics continue to be infected with B. 
burgdorferi. This is particularly due to the inability to isolate live bacteria from 
synovial fluid of patients that suffer from late stage Lyme arthritis (Carlson et al., 
1999; Shin et al., 2007). Different hypotheses have been proposed to explain the 
cause of continued synovitis in these patients in the absence of bacteria. Steere 
and Glickstein (2004) proposed the following hypotheses for this persistent 
arthritis: (1) B. burgdorferi might reside in a location that is not easily accessible to 
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antibiotics; (2) bacterial antigens, rather than live microbes, may have a continued 
presence in the synovial fluid and tissues; (3) the response to B. burgdorferi may 
cause autoimmunity due to T-cell epitope mimicry, and (4) infection may cause 
bystander activation of inflammatory cells. Recently, the “amber hypothesis” was 
proposed, postulating that antigens can become trapped in connective tissue (as 
if they were in amber), and then get released into the joint, eliciting a strong 
immune response (Wormser et al., 2012). This has been proposed as a possible 
explanation for why active infection is not observed in patients with antibiotic-
resistant Lyme arthritis (Wormser et al., 2012). This theory questions the persistent 
use of antibiotics in treatment of late-stage Lyme disease because antigens, rather 
than live microbes, would elicit the inflammatory immune response. Therefore, 
non-recommended treatments for Lyme arthritis need to be approached with 
caution, and other targets, such as the immune response, need to be considered 
for therapy. 
 
IV. Lyme Arthritis 
Various cells and cytokines have been implicated in the development of Lyme 
arthritis. Strong innate and adaptive immune responses are activated during the 
inflammatory process against B. burgdorferi; however, the exact mechanisms of 
Lyme arthritis are not fully understood. It has been demonstrated that during the 
innate response, neutrophils (Brown et al., 2003) and macrophages (Du Chateau 
et al., 1996) are activated in the synovial tissue. Similarly, there is an influx of 
complement proteins, as well as pro-inflammatory chemokines and cytokines, into 
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the synovial fluid of patients with Lyme arthritis (Shin et al., 2007). These innate 
factors lead to an inflammatory T cell-mediated response that often results in 
arthritis.  
 
i. Animal Models of Lyme Arthritis 
Animal models are used to study the immunopathogenic mechanisms of Lyme 
arthritis. The selection of an animal model depends on the purpose of the study 
because no animal model is able to combine all of the inflammatory events 
presented in humans with Lyme arthritis (Nardelli et al., 2008b). 
 
Infection of experimental mice with B. burgdorferi is used to study various features 
of Lyme arthritis. C3H/HeJ mice are the most commonly used mice for this disease 
model. Induction of Lyme arthritis is achieved by feeding of infected ticks or by 
injection of B. burgdorferi into the paws or between shoulder blades of the mice. 
Distinctive features of this model include synovitis that develops and resolves in 3-
6 weeks (Barthold et al., 1992) and that does not lead to cartilage or bone erosion 
(Barthold et al., 1992; Nardelli et al., 2010). In addition, this model exhibits a strong 
response by innate immune cells (Barthold et al., 1996, Nardelli et al., 2010). 
Contrary to this animal model, in humans, Lyme arthritis develops months to years 
after infection, and both innate and adaptive immune responses are important in 
this progression. Therefore, use of C3H mice in the study of Lyme arthritis may be 
best used to investigate the innate immune response following infection.   
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Using the infection model of disease, wild-type C57BL/6 mice are resistant to 
development of severe Lyme arthritis (Barthold et al., 1992, Ma et al., 1998). When 
C57BL/6 mice are injected with high doses of bacteria (up 2 x 105), they show 
minimal paw swelling, while C3H mice show severe paw swelling (Ma et al., 1998). 
However, infected C57BL/6 mice have a similar number of spirochetes as infected 
C3H mice, even though they develop mild arthritis (Ma et al., 1998). It has been 
proposed that differences in susceptibility between these two strains are linked to 
interleukin-10 (IL-10) production and its role in the immune response (Brown et al., 
1999, Ganapamo et al., 2000). C57BL/6 macrophages stimulated with B. 
burgdorferi produce more IL-10 than stimulated cells from C3H mice (Brown et al., 
1999). Furthermore, recombinant IL-10 down-regulates pro-inflammatory cytokine 
production by bone-marrow derived macrophages, while treatment with anti-IL-10 
antibody increases levels of pro-inflammatory cytokines produced by these 
macrophages (Gautam et al., 2012). These studies demonstrate the basic 
differences between C3H and C57BL/6 mice and the involvement of the anti-
inflammatory cytokine IL-10 in regulating the immune response in these mice 
following infection with B. burgdorferi.  
 
Involvement of IL-10 in regulating Lyme arthritis has led researchers to utilize IL-
10-deficient mice on both the C57BL/6 and C3H backgrounds to study the disease. 
C57BL/6 IL-10-deficient mice infected with B. burgdorferi have increased levels of 
paw swelling (Brown et al., 1999; Hansen et al., 2013), immune cell infiltrates 
(Sonderegger et al., 2012) and arthritis (Brown et al., 1999; Hansen et al., 2013) 
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while maintaining lower numbers of spirochetes than infected wild-type mice 
(Brown et al., 1999; Sonderegger et al., 2012). Sonderegger et al. (2012) noted 
the importance of adaptive immunity in this model, as there is direct involvement 
of T cells following infection (Sonderegger et al., 2012). Therefore, infected IL-10-
deficient mice may be a feasible model to study the involvement of the adaptive 
immune response in development of later stage Lyme arthritis, which is observed 
in humans (Sonderegger et al., 2012; Hansen et al., 2013).   
 
ii. T Cell Mediation of Lyme Arthritis 
While innate immunity is involved in causing joint inflammation during early 
infection, T cells– more specifically, T helper type 1 (Th1) cells– are involved in the 
development of later-stage Lyme arthritis. Th1 cells produce an important pro-
inflammatory cytokine, interferon-gamma (IFN-γ), which has been associated with 
the development of Lyme arthritis (Yssel et al., 1991). However, several groups 
were able to elicit Lyme arthritis in IFN-γ-deficient mice (Brown and Reiner, 1999; 
Christopherson et al., 2003; Burchill et al., 2003). These studies demonstrate that 
Th1 cells are not solely responsible for development of Lyme arthritis. Recently, a 
subset of T helper cells which produce interleukin-17 (IL-17), T helper type 17 
(Th17 cells), has been proposed to also play an important role in the 
immunopathogenesis of Lyme arthritis, particularly in later disease (Nardelli et al., 
2008b).  
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What factors support the hypothesis that IL-17-producing cells are involved in 
Lyme arthritis development? B. burgdorferi induces the production of IL-17 from 
cells of mice (Knauer et al., 2006) and humans with Lyme arthritis (Infante-Duarte 
et al., 2000). In addition, treatment with anti-IL-17 antibody in Borrelia-vaccinated 
and -infected mice prevented development of arthritis (Burchill et al., 2003; 
Nardelli, et al. 2004, 2005, 2008a). Also, Th17 cells have been found in the 
synovial fluid of Lyme arthritis patients (Codolo et al., 2008, 2013; Shen et al., 
2010). Furthermore, infected, arthritic mice produce increased amounts of IL-17, 
which can be reduced by antibodies to various Th17-cell-related cytokines 
(Amlong et al. 2006; Kotloski et al. 2008; Nardelli et al., 2008b). This evidence 
shows that B. burgdorferi is able to elicit an IL-17 response that may contribute to 
the development of Lyme arthritis.   
 
Other support for a potential role of IL-17-producing cells in the development of 
Lyme arthritis comes from experimental models of rheumatoid arthritis (RA) 
because of its similarities in pathology and clinical symptoms to Lyme arthritis. For 
example, in collagen-induced arthritis, it has been shown that IL-17 causes bone 
resorption and cartilage destruction (Lubberts et al., 2001, 2002). Furthermore, 
increased levels of IL-17 mRNA were noted in the synovia and lymph nodes in 
mice using a model of adjuvant arthritis (Bush et al., 2001). Similarly, Lubberts 
(2008) reported that IL-17-induced expression of NF-κB, which was necessary for 
osteoclastogenesis and bone resorption. These studies indicate the involvement 
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of IL-17 in development in several models of arthritis, supporting the concept that 
it may also be involved in the development of Lyme arthritis.  
 
iii. TNF-α and Lyme Arthritis  
Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine, produced by 
activated T cells and macrophages, that has been shown to play a role in 
rheumatoid arthritis pathogenesis (Katz et al., 2001). In addition, TNF-α plays a 
role in the immune response to B. burgdorferi and affects the pathogenesis of 
Lyme arthritis. Peripheral blood mononuclear cells (PBMCs) (Defosse and 
Johnson, 1992) and macrophages (Ma and Weis, 1993) produce TNF-α when 
incubated with B. burgdorferi. Additionally, synovial fluid from patients with Lyme 
arthritis was found to have higher levels of TNF-α than the synovial fluid of non-
arthritic patients (Defosse and Johnson, 1992). Currently, there are five FDA-
approved TNF-α inhibitors used as therapies for rheumatoid arthritis (Dinarello 
2005). Therefore, it is possible that TNF-α may be a viable target for the inhibition 
or prevention of Lyme arthritis. 
 
The role of these TNF-α inhibitors is to neutralize the cytokine, preventing binding 
to its receptors. However, about 30% to 50% of rheumatoid arthritis patients 
receiving TNF-α inhibitor therapy do not see improvements (Rubbert-Roth and 
Finckh, 2009). Surprisingly, however, Christopherson et al. (2003) demonstrated 
that neutralization of TNF-α actually increased the severity of arthritis in a mouse 
model of Lyme arthritis, while treatment with recombinant TNF-α ameliorated 
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disease. Another protective property of TNF-α in Lyme arthritis was demonstrated 
by Yrjänainen et al. (2007). Administration of antibodies to TNF-α did not 
ameliorate arthritic swelling; in addition, when neutralization of TNF-α was coupled 
with ceftriaxone therapy, the number of spirochetes actually increased (Yrjänainen 
et al., 2007). Both of these studies provide caution about the use of anti-TNF-α 
antibody for Lyme arthritis and highlight the need for further studies to elucidate 
the mechanism of TNF-α in its pathogenesis. While blocking TNF-α may be 
therapeutic for rheumatoid arthritis, it may not be for Lyme arthritis. This 
demonstrates that TNF-α may influence additional factors involved in the 
inflammatory response to B. burgdorferi. 
 
The pro-inflammatory cytokine IL-17 may be one such factor. The interactions 
between IL-17 and TNF-α are complex and cause various downstream 
inflammatory effects. Jovanovic et al. (1998) found that IL-17 can induce the 
production of TNF-α in human macrophages. In addition, in human-TNF-α 
transgenic mice, blocking IL-17 production led to a decreased number of 
osteoclasts and played a protective role in TNF-α-mediated arthritis (Zwerina et 
al., 2012). This study also demonstrated that IL-17 played a role not only in the 
inflammation of the joints, but also in joint destruction. Furthermore, IL-17 is able 
to induce the production of TNF-α and interleukin-1-beta (IL-1β) in the serum of 
rheumatoid arthritis patients (Chen et al., 2011).  Also, IL-17 was able to stimulate 
macrophages to release TNF-α along with IL-1β in vitro (Jovanovic et al., 1998). 
Additionally, IL-17 and TNF-α were shown by Katz et al. (2001) to act 
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synergistically in promoting inflammation. Addition of TNF-α and IL-17 to 
fibroblasts led to secretion of both interleukin-6 and interleukin-8. The additive 
effect of these two cytokines was also shown in cultures of rheumatoid arthritis 
synoviocytes, in which their actions induced hypoxia inducible factor 1 alpha, which 
is found in high levels in patients (Hot et al., 2012).  
 
While many studies show that IL-17 influences the production of TNF-α, others 
show that TNF-α influences the activity of IL-17. Iwamoto et al. (2007) showed that 
TNF-α assists in differentiation of mature dendritic cells that stimulate a Th17 
response. Also, use of the TNF-α inhibitor pentoxifylline to treat an animal model 
of rheumatoid arthritis reduces IL-17 levels in joint tissues. However, this treatment 
did not affect IL-17 levels in the periodontal-associated aspects of the experimental 
disease (Queiroz-Junior et al., 2013). Similar to this, Chen et al. (2011) showed 
that rheumatoid arthritis patients who responded to anti-TNF-α therapy produced 
fewer Th17 cells and IL-17 than untreated patients. However, patients who did not 
respond to treatment produced more Th17 cells and IL-17 (Chen et al., 2011). 
However, Koenders et al. (2006) showed that IL-17 acts independently of TNF-α 
in an in vivo rheumatoid arthritis model.  
 
These findings show the complex relationship between TNF-α and IL-17. In some, 
but not all, contexts, blocking TNF-α reduces IL-17 production. The role of TNF-α 
in inducing IL-17-mediated Lyme arthritis is not fully known.  
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V. Borreliacidal Antibody Response 
B. burgdorferi infection stimulates production of antibodies with highly specific 
killing activity against the spirochete. Borreliacidal antibodies specific to the outer 
surface proteins (Callister et al., 1994) cause the killing of the bacteria by activation 
of complement. Schmitz et al. (1990) demonstrated that injection of immune sera 
into infected mice protected against swelling, joint destruction and infection of 
tissues. Similarly, Lovrich et al. (1993) demonstrated that serum from infected 
hamsters was able to kill B. burgdorferi in vitro. Production of these borreliacidal 
antibodies can be used to determine protection against B. burgdorferi. It was 
shown that the presence of borreliacidal antibodies correlates with elimination of 
B. burgdorferi from tissues (Schmitz et al., 1991; Creson et al., 1996), while the 
total antibody response is sustained for a longer amount of time (Padilla et al., 
1996). Collectively, these studies show that borreliacidal antibody production is 
important for protection against B. burgdorferi. 
 
Different outer-surface proteins, including OspA, OspB and OspC, were identified 
as immunogens that produce borreliacidal antibodies. A recombinant OspA 
vaccine was made available on the market in 1998 but was removed after 4 years. 
Both of the clinical trials for the recombinant OspA vaccine (Sigal et al., 1998; 
Steere et al., 1998) required two boosters, underlining the importance of 
maintaining a strong humoral immune response in the protection against B. 
burgdorferi, which is the basis for developing effective Lyme borreliosis vaccines. 
Prior to this, Padilla et al. (1996) demonstrated that borreliacidal antibody titers 
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waned quickly after vaccination. By determining the immune mechanisms that 
influence microbial clearance through borreliacidal antibodies, additional factors 
that induce protection can be identified.   
 
VI. HYPOTHESIS AND SPECIFIC AIMS 
Arthritis is one of the major complications of late stage Lyme borreliosis. Cytokines 
play an important role in mediation of inflammation elicited by B. burgdorferi 
infection. Specifically, IL-17 has been implicated in development of Lyme arthritis 
(Infante-Duarte et al., 2000; Burchill et al., 2003; Nardelli et al., 2004, 2005, 2008a; 
Knauer et al., 2006; Hansen et al., 2013). However, the role of the pro-
inflammatory cytokine TNF-α remains to be further elucidated. Incubation of 
peripheral blood mononuclear cells (Defosse and Johnson, 1992) and 
macrophages (Ma and Weis, 1993) with B. burgdorferi induce production of TNF-
α. However, a protective role for TNF-α in Lyme arthritis was demonstrated 
(Christopherson et al., 2003; Yrjänainen et al., 2007). Studies of rheumatoid 
arthritis and psoriasis indicate that TNF-α can regulate IL-17 (Moran et al., 2009; 
Chen et al., 2011), while others indicate an independent relationship between TNF-
α and IL-17 in arthritis development (Koenders et al., 2006; Iwamoto et al., 2007). 
However, the effect of TNF-α on IL-17 production during B. burgdorferi infection 
has not been explored. The objective of this research is to elucidate the role of 
TNF-α and IL-17 in the inflammatory process of Lyme arthritis. The hypothesis of 
this thesis is that TNF-α will regulate the immune response to B. burgdorferi 
infection by decreasing IL-17 production.    
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The following specific aims of this proposal are: 
1. Determine the effect of TNF-α on IL-17 in the immune response to B. 
burgdorferi infection. The working hypothesis of this aim is that TNF-α will 
decrease IL-17 production following B. burgdorferi infection.  
 
2. Determine the effects of TNF-α on the borreliacidal antibody response 
following infection with B. burgdorferi.  The working hypothesis of this 
aim is that anti-TNF-α treatment of B. burgdorferi-infected mice will inhibit 
borreliacidal antibody production, which will be reversed by also blocking 
IL-17. 
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CHAPTER 2: MATERIALS AND METHODS 
I. Mice 
Female and male, 6 to-12 week old wild-type and IL-10-deficient C57BL/6 mice 
were obtained from Dr. J.-A. Lyons (University of Wisconsin-Milwaukee). These 
mice were housed and cared for in the animal facility at the University of 
Wisconsin-Milwaukee. Food and water were provided ad libitum. The protocols 
and guidelines were reviewed and approved by the University of Wisconsin-
Milwaukee Institutional Animal Care and Use Committee. 
  
II. Infection of Mice with B. burgdorferi  
Borrelia burgdorferi strain 297 was provided by S. M. Callister (Gundersen 
Lutheran Medical Center, La Crosse, WI). B. burgdorferi organisms were grown in 
Barbour-Stoenner-Kelly (BSK) medium for 2-4 days at 34ºC. Mice were 
anesthetized with isoflurane in a nose-to-mouth cup and infected subcutaneously 
with 106 spirochetes (0.05 ml) into the hind paws.  
 
III. Administration of Anti-Cytokine Antibodies 
Anti-IL-17 and isotype control antibodies were purchased from Affymetrix 
eBioscience (San Diego, CA), while anti-TNF-α and isotype control antibodies 
were purchased from R & D Systems (Minneapolis, MN). Antibodies were 
reconstituted in phosphate buffered saline (PBS) to achieve a concentration of 2.5 
µg/ml. One day after infection, two groups of 5 infected mice were anesthetized 
with isoflurane and then injected in the hind paw with 2.5 µg of TNF-α antibody. 
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One of these two anti-TNF-α antibody-treated groups was simultaneously injected 
with 2.5 µg of anti-IL-17 antibody, while the other was simultaneously injected with 
an isotype control antibody. A third group of infected mice was injected with anti-
IL-17 antibody and an isotype control antibody. An additional group of infected 
mice was injected with isotype control antibodies. These antibody treatments were 
administered for four consecutive days following the initial treatment.  
 
IV. Assessment of Inflammation 
Mice were anesthetized with isoflurane in a nose-to-mouth cup. Using a Vernier 
caliper, hind paws were measured for thickness and width, and the average of 
these two measurements was calculated as the “mean paw value”. Swelling of the 
hind paws was measured prior to injections on the day of infection and at the time 
of sacrifice, 8 days post infection. The measurements of hind paw swelling on day 
8 after infection were compared to the measurements of paw thickness prior to 
infection. Since the different groups of mice did not have equal values of initial paw 
thickness, the overall increase in swelling from the day of infection to day 8 after 
infection was also determined.  
 
V. Cell Culture 
Spleens were collected and used for in vitro culture studies to assess production 
of IL-17. Single-cell suspensions were obtained by passing the tissue through a 
100-µm nylon cell strainer into Roswell Park Memorial Institute 1640 (RPMI) 
medium. 2 x106 spleen cells in RPMI medium were incubated at 37°C in 5% CO2, 
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with or without 105 B. burgdorferi 297 organisms in BSK medium. Supernatants 
were collected after 18 and 24 hours of incubation. 
 
VI. In Vitro Administration of Anti-Cytokine Antibodies 
In another study, wild-type and IL-10-deficient C57BL/6 mice were infected 
subcutaneously with 106 spirochetes (0.05 ml) in the hind paws. Non-infected 
control mice received an injection of BSK medium. Ten days after infection, mice 
were sacrificed, and single-cell suspensions were prepared from spleens, as 
described previously. 2 x 106 spleen cells in RPMI medium were incubated at 37°C 
in 5% CO2, with or without 105 B. burgdorferi 297 organisms in BSK medium in a 
total volume of 1 ml. Additionally, cells were incubated with isotype-control 
antibodies or with anti-TNF-α antibodies, anti-IL-17 antibodies, or both anti-TNF-α 
and anti-IL-17 antibodies. Antibodies were added to wells in concentrations of 2.5 
µg/ml, 5 µg/ml, or 10 µg/ml. Cells from non-infected mice were incubated with or 
without spirochetes and with or without 2.5 µg/ml anti-TNF-α antibodies, anti-IL-17 
antibodies, or both anti-TNF-α and anti-IL-17 antibodies. Supernatants were 
collected after 24 hours of incubation. 
 
VII. ELISA 
Supernatants were analyzed for IL-17 production using the Mouse IL-17A 
(homodimer) ELISA Ready-SET-Go! Kit (Affymetrix eBioscience) according to the 
manufacturer’s instructions. Samples were analyzed in duplicates and plates were 
read at 450nm.  
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VIII. Borreliacidal Antibody Assay 
Serum was collected from mice for the assessment of borreliacidal antibodies. 
Equal amounts of serum were pooled within a group. Each serum sample was heat 
inactivated in a 56°C water bath for 30 minutes, diluted 1:20 in BSK medium, and 
then serially diluted to 1:40,960. Subsequently, 105 B. burgdorferi strain 297 
organisms in 50 µL of BSK medium were added to the diluted wild-type serum, 
and 104 B. burgdorferi strain 297 organisms were added to the diluted IL-10-
deficient serum. Then, 10 µL of guinea pig complement were added, and the 
samples were incubated for 16 hours at 32°C. After incubation, samples were 
examined for motile B. burgdorferi (at least 30 fields per sample) using darkfield 
microscopy. The borreliacidal antibody titer was the inverse of the first dilution that 
showed no live organisms. Controls included heat-inactivated serum from naïve 
mice incubated with B. burgdorferi and guinea pig complement, B. burgdorferi 
incubated with guinea pig complement, and B. burgdorferi incubated in BSK 
medium. 
 
IX. Statistics 
The results of some studies were expressed as mean ± standard error of the mean 
(SEM) and analyzed using a two-tailed Student's t-Test to determine the level of 
significance. Other data were analyzed by one-way analysis of variance (ANOVA) 
followed by the Tukey-Kramer post-hoc test. All P-values were calculated with the 
alpha level set at 0.05 prior to initiation of experiments.  
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CHAPTER 3: RESULTS 
I. Paw inflammation after antibody treatment of B. burgdorferi-infected mice.  
B. burgdorferi-infected wild-type and IL-10-deficient mice were treated for four 
consecutive days after infection with anti-TNF-α antibodies, anti-IL-17 antibodies, 
or both anti-TNF-α and anti-IL-17 antibodies. Paws were measured prior to 
infection and at the time of sacrifice (day 8 after infection). The hind paws of 
infected but untreated wild-type mice were larger on day 8 after infection compare 
to baseline levels. This increase was not significant, however (P = 0.07; data not 
shown). By contrast, the hind paws of infected wild-type mice treated with anti-
TNF-α antibodies were significantly larger on day 8 after infection compared to 
baseline levels (P = 0.006; data not shown). In addition, no significant differences 
in hind paw swelling were observed between days 0 and 8 of infection in wild-type 
mice treated with anti-IL-17 antibodies, alone or also with anti-TNF-α antibodies 
(data not shown).  
 
We then measured the overall change in hind paw swelling in infected wild-type 
mice by subtracting measurements at day 8 from baseline values. The change in 
paw swelling of infected, anti-TNF-α antibody-treated mice was slightly, but not 
significantly, greater than the overall change of swelling in infected but untreated 
mice (Fig. 1). Additionally, the overall change in swelling in anti-IL-17 antibody-
treated mice was slightly, but insignificantly, less than the control group. However, 
the overall change in paw swelling in anti-TNF-α antibody-treated mice was 
significantly greater than the degree of swelling in anti-IL-17 antibody-treated mice 
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(P = 0.045). Administration of antibodies against both IL-17 and TNF-α did not 
significantly change the magnitude of paw swelling compared to infected mice 
treated with anti-IL-17 antibodies (Fig. 1). 
 
 
 
 
In contrast to infected wild-type mice, all antibody-treated groups of B. burgdorferi-
infected IL-10-deficient mice exhibited larger paws at day 8 after infection 
compared to baseline levels. At day 8 after infection, significantly larger paws were 
exhibited by infected IL-10-deficient mice that were untreated (P = 0.0008) or 
treated with anti-TNF-α (P = 1 x 10-6) or anti-IL-17 (P = 6 x 10-5) antibodies, 
compared to their baseline paw thickness (data not shown). Infected IL-10-
deficient mice treated with both antibodies exhibited larger paws by day 8 after 
infection. However, this increase was not significant (P = 0.06; data not shown).  
 
Compared to the overall change in paw swelling of infected but untreated IL-10-
deficient mice, a significantly greater overall change in swelling was observed in 
Figure 1. Overall change in paw swelling following treatment of B. burgdorferi-infected 
wild-type mice. Mice were infected with B. burgdorferi and then injected with antibodies to 
TNF-α, IL-17, both cytokines, or neither cytokine for four days. Treatment with TNF-α 
antibodies slightly, but not significantly, increased paw swelling in mice that were otherwise 
not treated or treated with anti-IL-17 antibodies. Values indicate means ± SEM. Groups 
consisted of 4-5 mice each. 
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mice treated with anti-TNF-α (P = 0.0001) or anti-IL-17 (P = 0.01) antibodies (Fig. 
2). However, the overall change in paw swelling in infected mice treated with anti-
IL-17 antibodies was not different than the change in paw swelling by mice treated 
with antibodies to both IL-17 and TNF-α. 
 
 
 
 
 
II. Effects of anti-cytokine antibodies on IL-17 production in B. burgdorferi-
infected, wild-type mice.  
To assess the involvement of TNF-α on production of IL-17 during B. burgdorferi 
infection, C57BL/6 wild-type mice were treated with anti-TNF-α and/or anti-IL-17 
antibodies for four consecutive days after infection. Eight days after infection, 
spleen cells were obtained and incubated in the absence (Fig. 3) or presence (Fig. 
4) of B. burgdorferi for 18 hours. When incubated for 18 hours, unstimulated spleen 
cells from infected, anti-TNF-α antibody-treated wild-type mice produced 
Figure 2. Overall change in paw swelling following treatment of B. burgdorferi-infected 
IL-10-deficient mice. Mice were infected with B. burgdorferi and then injected with antibodies 
to TNF-α, IL-17, both cytokines, or neither cytokine for four days. Treatment with anti-TNF-α 
or anti-IL-17 antibodies resulted in a significantly greater overall change in paw swelling 
compared to untreated controls. However, additional treatment with anti-TNF-α did not result 
in swelling changes in anti-IL-17 antibody-treated mice. Values indicate means ± SEM. 
Groups consisted of 4-5 mice each. *, P ≥ 0.05. 
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significantly greater amounts of IL-17 than unstimulated spleen cells from 
untreated, infected mice (56 pg/ml vs. 30 pg/ml; P = 0.05; Fig. 3). Surprisingly, 
unstimulated spleen cells from infected, anti-IL-17 antibody-treated wild-type mice 
produced significantly more IL-17 than unstimulated spleen cells from untreated, 
infected mice (68 pg/ml vs. 30 pg/ml; P = 0.005; Fig. 3). Unstimulated spleen cells 
from infected mice injected with antibodies against both IL-17 and TNF-α produced 
less IL-17 than unstimulated cells from infected, anti-IL-17 antibody treated mice 
(45 pg/ml vs. 68 pg/ml). However, this decrease in IL-17 production due to 
administration of anti-TNF-α antibodies did not achieve statistical significance (Fig. 
3). 
 
 
 
 
 
Additionally, cells from these groups of antibody-treated, B. burgdorferi-infected 
wild-type mice were stimulated in vitro with B. burgdorferi for 18 hours. Stimulation 
of spleen cells from infected, anti-TNF-α antibody-treated wild-type mice induced 
Figure 3. Production of IL-17 by unstimulated spleen cells from B. burgdorferi-infected, 
antibody (Ab)-treated wild-type mice after 18 hours of incubation. Eight days after 
infection, spleen cells from Ab-treated, wild-type mice were incubated for 18 hours in the 
absence of B. burgdorferi. Unstimulated cells from anti-TNF-α and anti-IL-17 Ab-treated mice 
produced significantly more IL-17 than unstimulated cells from untreated, infected mice. 
Additional treatment with anti-TNF-α Ab did not affect IL-17 production by cells of anti-IL-17 
Ab-treated mice. Values indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 
0.05. 
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slightly, but insignificantly, more IL-17 than stimulated spleen cells from infected 
but untreated mice (67 pg/ml vs. 45 pg/ml; P = 0.08; Fig. 4). B. burgdorferi-
stimulated spleen cells harvested from infected, anti-IL-17 antibody-treated mice 
produced similar amounts of IL-17 than cells from infected but untreated mice (42 
pg/ml vs. 45 pg/ml; Fig. 4). In addition, stimulated cells from infected mice treated 
with anti-IL-17 antibody produced similar amounts of IL-17 than cells from infected 
mice treated with both anti-IL-17 and anti-TNF-α antibodies (42 pg/ml vs. 48 pg/ml; 
Fig. 4). 
 
 
 
 
 
The effects of in vitro stimulation with B. burgdorferi, for 18 hours, on IL-17 
production by these cells were then compared. Incubation of cells from infected, 
untreated wild-type mice with B. burgdorferi slightly, but insignificantly, increased 
production of IL-17 (Fig. 5). Similar findings were observed among stimulated cells 
obtained from infected mice that were treated with anti-TNF-α antibodies (Fig. 5). 
Figure 4. Production of IL-17 by B. burgdorferi-stimulated spleen cells from B. 
burgdorferi-infected, Ab-treated wild-type mice after 18 hours of incubation. Eight days 
after infection, spleen cells from Ab-treated, wild-type mice were incubated for 18 hours in the 
presence of B. burgdorferi. Stimulated cells from anti-TNF-α Ab-treated mice produced 
slightly, but not significantly, more IL-17 than stimulated cells from untreated, infected mice. 
Anti-TNF-α Ab treatment did not affect IL-17 production by cells from mice treated with anti-
IL-17 Abs. Values indicate means ± SEM. Groups consisted of 4-5 mice each.  
28 
 
By contrast, stimulation of cells from infected, anti-IL-17 antibody-treated mice 
significantly decreased IL-17 production (Fig. 5). 
 
 
 
 
 
Spleen cells were also incubated with or without B. burgdorferi for 24 hours. 
Unstimulated cells from infected, anti-TNF-α antibody-treated mice produced 
slightly, but insignificantly, less IL-17 than spleen cells from infected but untreated 
wild-type mice (28 pg/ml vs. 44 pg/ml; P = 0.13; Fig. 6). However, unstimulated 
cells from infected, anti-IL-17 antibody-treated mice produced significantly less IL-
17 than unstimulated cells from infected but untreated mice (21 pg/ml vs. 44 pg/ml; 
P = 0.02; Fig. 6). However, addition of anti-TNF-α antibody to infected, anti-IL-17 
antibody-treated mice did not significantly affect IL-17 production by spleen cells 
incubated in the absence of B. burgdorferi for 24 hours (32 pg/ml vs. 21 pg/ml; Fig. 
6).   
Figure 5. Effect of in vitro stimulation with B. burgdorferi for 18 hours on 
production of IL-17 from infected mice treated with anti-cytokine Abs. Stimulation 
with B. burgdorferi (darker bars) caused a slight, but insignificant, increase in IL-17 
production by spleen cells obtained from infected mice that were untreated or treated 
with anti-TNF-α Abs. By contrast, stimulation caused a significant decrease in IL-17 
production by cells obtained from infected mice treated with anti-IL-17 Abs. Values 
indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05. 
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After 24 hours of incubation, B. burgdorferi-stimulated spleen cells from infected, 
anti-TNF-α antibody-treated mice produced similar amounts of IL-17 as  stimulated 
cells from infected but untreated mice (18 pg/ml vs. 26 pg/ml; P = 0.36; Fig. 7). 
Also, stimulated cells from infected, anti-IL-17 antibody-treated mice produced 
less, although statistically similar, amounts of IL-17 as stimulated cells from 
infected but untreated mice (9 pg/ml vs. 26 pg/ml; P = 0.13; Fig 7). Interestingly, 
stimulated cells harvested from infected mice treated with both anti-IL-17 and anti-
TNF-α antibodies did not produce detectable levels of IL-17. However, this 
difference was not statistically different from stimulated spleen cells from infected, 
anti-IL-17 antibody-treated mice (Fig. 7).  
Figure 6. Production of IL-17 by unstimulated spleen cells from B. burgdorferi-
infected, Ab-treated wild-type mice after 24 hours of incubation. Eight days after 
infection, spleen cells from Ab-treated, wild-type mice were incubated for 24 hours in the 
absence of B. burgdorferi. Unstimulated cells from anti-TNF-α Ab-treated mice produced 
a similar amount of IL-17 than unstimulated cells from untreated, infected mice. By 
contrast, cells from anti-IL-17 Ab-treated mice produced significantly less IL-17 than cells 
from control mice. The level of IL-17 produced by cells from anti-IL-17 Ab-treated mice 
was comparable to that of cells from anti-IL-17 and -TNFα Ab-treated mice. Values 
indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05. 
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The effects of in vitro stimulation with B. burgdorferi, for 24 hours, on IL-17 
production by these cells were then compared. Incubation of cells from infected, 
untreated wild-type mice with B. burgdorferi decreased production of IL-17 by cells 
from all groups of treated mice (Fig. 8). However, a statistically significant decrease 
in IL-17 production was observed following stimulation of cells only from infected 
mice treated with anti-TNF-α and anti-IL-17 antibodies. (Fig. 8). 
 
 
Figure 7. Production of IL-17 by B. burgdorferi-stimulated spleen cells from B. 
burgdorferi-infected, Ab-treated wild-type mice after 24 hours of incubation. Eight 
days after infection, spleen cells from Ab-treated, wild-type mice were incubated for 24 
hours in the presence of B. burgdorferi. Stimulated cells from anti-TNF-α and anti-IL-17 
Ab-treated mice produced a similar amount of IL-17 as unstimulated cells from untreated, 
infected mice. By contrast, cells from dual-Ab-treated mice produced undetectable 
amounts of IL-17. While this was significantly less compared to cells of untreated or anti-
TNF-α Ab-treated mice, it was not significantly different compared to cells of IL-17 Ab-
treated mice. Values indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 
0.05. 
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III. Effects of anti-cytokine antibodies on IL-17 production in B. burgdorferi-
infected, IL-10-deficient mice. 
The effect of TNF-α on IL-17 production following B. burgdorferi infection in the 
absence of IL-10 was then determined. B. burgdorferi-infected, IL-10-deficient 
mice were treated for four consecutive days with anti-TNF-α antibody and/or anti-
IL-17 antibodies. Spleen cells were collected eight days after infection and 
incubated with or without B. burgdorferi. Eighteen hours after incubation, 
unstimulated spleen cells obtained from all groups of mice produced low or 
undetectable levels of IL-17 (data not shown). By contrast, stimulated spleen cells 
from anti-TNF-α antibody-treated mice produced significantly greater amounts of 
IL-17 than stimulated cells from non-treated mice after 18 hours of stimulation with 
B. burgdorferi (27 pg/ml vs. 0.39 pg/ml; P = 0.02; Fig. 9). Stimulated cells from 
Figure 8. Effect of in vitro stimulation with B. burgdorferi for 24 hours on 
production of IL-17 from infected mice treated with anti-cytokine Abs. Stimulation 
with B. burgdorferi (darker bars) for 24 hours caused a decrease in IL-17 production by 
spleen cells obtained from infected mice treated with anti-cytokine Abs. A statistically 
significant decrease in IL-17 production was observed following stimulation of cells from 
dual-Ab-treated mice. Values indicate means ± SEM. Groups consisted of 4-5 mice each. 
*, P ≥ 0.05. 
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infected, IL-10-deficient mice treated with anti-IL-17 antibodies produced an 
undetectable amount of IL-17 after 18 hours of incubation. Additional treatment of 
these mice with anti-TNF-α antibodies did not lead to a change in IL-17 production 
following stimulation for 18 hours (Fig. 9). 
 
 
 
 
 
Cells from these mice were also incubated in the presence or absence of B. 
burgdorferi for 24 hours (Fig. 10). Unstimulated cells from infected, IL-10-deficient 
mice treated with anti-TNF-α antibody produced IL-17 after 24 hours of incubation. 
However, these levels were equal to IL-17 production by unstimulated cells from 
untreated mice (27 pg/ml vs. 25 pg/ml; P = 0.82; Fig. 10). Similarly, unstimulated 
cells collected from infected, anti-IL-17 antibody-treated mice  
Figure 9. Production of IL-17 by B. burgdorferi-stimulated spleen cells from B. 
burgdorferi-infected, Ab-treated IL-10-deficient mice after 18 hours of incubation. Eight 
days after infection, spleen cells from Ab-treated, IL-10-deficient mice were incubated for 18 
hours in the presence of B. burgdorferi. Stimulated cells from anti-TNF-α Ab-treated mice 
produced significantly, more IL-17 than stimulated cells from untreated, infected mice. Values 
indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05. 
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produced a similar amount of IL-17 as unstimulated cells from infected, untreated 
mice (24 pg/ml vs. 25 pg/ml; P = 0.92; Fig. 10). Additionally, treatment of infected 
mice with antibodies against both IL-17 and TNF-α did not affect the production of 
IL-17 from stimulated spleen cells compared to infected, anti-IL-17 antibody-
treated mice (23 pg/ml vs. 24 pg/ml; P = 0.87; Fig. 10). Overall, unstimulated cells 
from infected, IL-10 deficient mice produced consistent levels of IL-17 between all 
four different treatment groups after incubation for 24 hours. 
 
Additionally, production of IL-17 was not significantly different between spleen cells 
from the untreated and single-antibody-treated groups of infected, IL-10-deficient 
mice after incubation with B. burgdorferi for 24 hours (Fig. 11). 
Figure 10. Production of IL-17 by unstimulated spleen cells from B. burgdorferi-
infected, Ab-treated IL-10-deficient mice after 24 hours of incubation. Eight days after 
infection, spleen cells from Ab-treated, IL-10-deficient mice were incubated for 24 hours 
in the absence of B. burgdorferi. No differences in IL-17 production were observed among 
cells from any of the Ab-treated mice. Values indicate means ± SEM. Groups consisted of 
4-5 mice each.  
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Stimulated spleen cells that were obtained from B. burgdorferi-infected mice that 
were treated with anti-TNF-α antibodies produced similar amounts of IL-17 as did 
cells from infected, untreated mice (25 pg/ml vs. 23 pg/ml; Fig. 11). Likewise, 
stimulated cells from infected, IL-10-deficient mice treated with anti-IL-17 antibody 
produced similar levels of IL-17 as spleen cells from infected, untreated mice (Fig. 
11). Injection of anti-TNF-α and anti-IL-17 antibodies to infected IL-10-deficient 
mice did not significantly alter the production of IL-17 by spleen cells compared to 
that of infected mice treated with only anti-IL-17 antibody (Fig. 11).  
 
IV. Production of IL-17 by wild-type cells following in vitro antibody 
treatment. 
Spleen cells were harvested from B. burgdorferi-infected wild-type mice 10 days 
after infection. The cells were incubated with the spirochete and with antibodies to 
Figure 11. Production of IL-17 by B. burgdorferi-stimulated spleen cells from B. 
burgdorferi-infected, Ab-treated IL-10-deficient mice after 24 hours of incubation. 
Eight days after infection, spleen cells from Ab-treated, IL-10-deficient mice were 
incubated for 24 hours in the presence of B. burgdorferi. Cells from anti-TNF-α Ab-treated 
mice produced a similar amount of IL-17 as cells from untreated mice. Although the 
amount of IL-17 produced by cells of dual-Ab-treated mice was significantly greater than 
controls, it was similar to that of cells from anti-IL-17 Ab-treated mice.  Values indicate 
means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05. 
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TNF-α and/or IL-17 for 24 hours to provide information about the effect of TNF-α 
on IL-17 production without the variables associated with treatment in vivo. We 
first treated stimulated spleen cells obtained from wild-type, B. burgdorferi-infected 
mice with 2.5 µg of antibodies for 24 hours. Cells that were incubated with 2.5 µg 
of anti-TNF-α antibody produced significantly more IL-17 than non-treated cells (32 
pg/ml vs. 17 pg/ml; P = 0.037; Fig. 12). In contrast, cells incubated with 2.5 µg of 
anti-IL-17 antibody produced a similar amount of IL-17 as untreated cells (Fig. 12). 
Furthermore, treatment with both anti-IL-17 and anti-TNF-α antibodies did not 
affect production of IL-17 compared to cells treated with anti-IL-17 antibody alone 
(Fig. 12).  
 
 
 
 
 
 
We then treated stimulated spleen cells from wild-type B. burgdorferi-infected mice 
with a greater (5 µg) concentration of antibodies and measured the production of 
IL-17 (Fig. 13). Treatment with anti-TNF-α antibody did not affect IL-17 production 
Figure 12. Effect of 2.5 µg in vitro anti-cytokine Abs on production of IL-17 in wild-type 
cells. Wild-type mice were infected with B. burgdorferi. Eight days later, spleen cells were 
incubated with 2.5 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and antil-IL-17 Ab 
for 24 hours. Cells treated with anti-TNF-α Ab produced significantly more IL-17 than 
untreated cells. However, anti-TNF-α Ab treatment did not affect IL-17 production by cells 
treated with anti-IL-17 Ab. Values indicate means ± SEM. Groups consisted of 4-5 mice each. 
*, P ≥ 0.05. 
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compared to non-treated cells (Fig. 13). Similarly, treatment of cells with anti-IL-17 
antibody did not change IL-17 levels in comparison to non-treated cells (Fig. 13). 
However, cells that were treated with both anti-IL-17 and anti-TNF-α antibodies 
produced significantly greater levels of IL-17 than cells treated with just anti-17 
antibody (35 pg/ml vs 25 pg/ml; P = 0.005; Fig. 13).  
 
 
 
 
 
In addition, a concentration of 10 µg of each antibody was administered to the 
spleen cells harvested from infected wild-type mice. However, cells from all four 
groups produced similar amounts of IL-17 (Fig. 14). Spleen cells incubated with 
anti-TNF-α antibody did not affect production of IL-17 compared to untreated cells. 
Similarly, anti-IL-17 antibody-treated cells produced similar amounts of IL-17 as 
non-treated cells. Additionally, anti-IL-17 antibody-treated cells produced similar 
amounts of IL-17 as cells treated with antibodies against both IL-17 and TNF-α 
(Fig. 14). 
Figure 13. Effect of 5 µg in vitro anti-cytokine Abs on production of IL-17 in 
wild-type cells cells. Wild-type mice were infected with B. burgdorferi. Eight days 
later, spleen cells were incubated with 5 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both 
Abs for 24 hours. Anti-TNF-α Ab treatment of IL-17 Ab-treated cells caused a 
significant increase in IL-17 production compared to cells treated with anti-IL-17 Ab 
alone. Values indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05. 
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V. Production of IL-17 by IL-10-deficient cells following in vitro antibody 
treatment.  
Spleen cells were harvested from B. burgdorferi-infected, IL-10-deficient mice 10 
days after infection. The cells were incubated with the spirochete and with 
antibodies to TNF-α and/or IL-17 for 24 hours to provide information about the 
effect of TNF-α on IL-17 production without the variables associated with treatment 
in vivo. Spleen cells harvested from infected IL-10-deficient mice and incubated 
with 2.5 µg anti-TNF-α antibody produced a similar amount of IL-17 as untreated 
cells (84 pg/ml vs. 88 pg/ml; Fig. 15). By contrast, spleen cells treated with 2.5 µg 
of anti-IL-17 antibody produced a significantly smaller amount of IL-17 than non-
treated cells (43 pg/ml vs. 84 pg/ml; P = 0.0004; Fig. 15). Contrary to that which 
was observed in wild-type cells, treatment with both antibodies led to an even 
greater decrease in IL-17 production (29 pg/ml). However, this decrease was not 
statistically different than IL-17 production from anti-IL-17 antibody-treated cells (P 
= 0.12; Fig. 15).    
Figure 14. Effect of 10 µg in vitro anti-cytokine Abs on production of IL-17 in wild-type 
cells. Wild-type mice were infected with B. burgdorferi. Eight days later, spleen cells were 
incubated with 10 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and antil-IL-17 Ab 
for 24 hours. Anti-TNF-α Ab treatment had no effect on IL-17 production at this concentration. 
Values indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05. 
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We then treated stimulated spleen cells from IL-10-deficient, B. burgdorferi-
infected mice with a greater (5 µg) concentration of antibodies and measured the 
production of IL-17 (Fig. 16). Spleen cells that were harvested from infected mice 
and treated with anti-TNF-α antibody produced similar amounts of IL-17 as 
untreated cells from infected mice (Fig. 16). As expected, cells treated with anti-
IL-17 antibody produced significantly less IL-17 than non-treated cells (30 pg/ml 
vs. 73 pg/ml; P = 0.009; Fig. 16). However, addition of anti-TNF-α antibodies to 
cells treated with anti-IL-17 antibodies did not affect IL-17 production (28 pg/ml vs. 
30 pg/ml; P = 0.90; Fig. 16).  
Figure 15. Effect of 2.5 µg in vitro anti-cytokine Abs on production of IL-17 in IL-10-
deficient cells. IL-10-deficient mice were infected with B. burgdorferi. Eight days later, spleen 
cells were incubated with 2.5 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and antil-
IL-17 Ab for 24 hours. Cells treated with anti-IL-17 Ab produced significantly less IL-17 than 
untreated cells, but cells treated with anti-TNF-α Ab alone had no effect. Anti-TNF-α Ab 
treatment did not affect IL-17 production by cells also treated with anti-IL-17 Ab. Values 
indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05. 
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In addition, 10 µg of antibodies were administered to spleen cells collected from B. 
burgdorferi-infected, IL-10-deficient mice (Fig. 17). Spleen cells incubated with 
anti-TNF-α antibody produced similar amounts of IL-17 as non-treated cells (P = 
0.70; Fig. 17). As expected, treatment of cells with anti-IL-17 antibody significantly 
decreased IL-17 production compared to untreated cells (24 pg/ml vs. 69 pg/ml; P 
= 0.002; Fig. 17). However, the production of IL-17 by anti-IL-17 antibody-treated 
cells was similar to the production of IL-17 by cells treated with both anti-TNF-α 
and anti-IL-17 antibodies (P = 0.50). 
  
Figure 16. Effect of 5 µg in vitro anti-cytokine Abs on production of IL-17 in IL-10-
deficient cells. IL-10-deficient mice were infected with B. burgdorferi. Eight days later, spleen 
cells were incubated with 5 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and antil-
IL-17 Ab for 24 hours. Cells treated with anti-IL-17 Ab, with or without anti-TNF-α Ab, produced 
significantly less IL-17 than untreated cells. Cells treated with anti-TNF-α Ab alone had no 
effect on IL-17 production. Values indicate means ± SEM. Groups consisted of 4-5 mice each. 
*, P ≥ 0.05. 
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Overall, spleen cells from B. burgdorferi-infected, IL-10-deficient mice produced 
an increased amount of IL-17 than spleen cells from infected wild-type mice. 
Treatment of spleen cells from infected, IL-10 deficient mice with 2.5 µg or 10 µg 
of anti-TNF-α antibody induced a significantly greater amount of IL-17 than 
treatment of corresponding wild-type cells (P = 5 x 10-6 and 0.009; Fig. 18 and data 
not shown, respectively). However, these increases were also observed among 
untreated cells (Fig. 18 and data not shown). In contrast, no differences were 
observed in production of IL-17 by wild-type and IL-10-deficient cells after 
incubation with anti-IL-17 antibodies or with both anti-IL-17 and anti-TNF-α 
antibodies (Fig. 18 and data not shown). No changes in IL-17 production were 
observed between wild-type and IL-10-deficient cells treated with 5 µg of antibody 
(data not shown). 
Figure 17. Effect of 10 µg in vitro anti-cytokine Abs on production of IL-17 in IL-10-
deficient cells. IL-10-deficient mice were infected with B. burgdorferi. Eight days later, spleen 
cells were incubated with 10 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and antil-
IL-17 Ab for 24 hours. Cells treated with anti-IL-17 Ab produced significantly less IL-17 than 
untreated cells. Cells treated with anti-TNF-α Ab alone, or in addition to anti-IL-17 Ab, had no 
effect on IL-17 production. Values indicate means ± SEM. Groups consisted of 4-5 mice each. 
*, P ≥ 0.05. 
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Interestingly, within all four treated groups, there were no significant differences in 
production of IL-17 with an increased amount of their respective antibodies (data 
not shown). Surprisingly, treatment of spleen cells with increased concentrations 
of anti-IL-17 antibodies did not significantly reduce IL-17 levels in either IL-10 
deficient or wild-type mice, although trends toward less production were observed 
(data not shown). Spleen cells from infected wild-type or IL-10 deficient mice, when 
incubated with anti-TNF-α antibodies, exhibited no dose-response in IL-17 
production, even when anti-IL-17 antibodies were also added (data not shown).  
 
VI. Borreliacidal antibody titers.  
The purpose of this experiment was to evaluate the killing activity of serum 
antibodies directed against B. burgdorferi in wild-type and IL-10-deficient mice 
treated with anti-TNF-α and/or anti-IL-17 antibodies. A one-fold greater difference 
was noted in borreliacidal antibody titers of infected, anti-TNF-α antibody-treated 
Figure 18. Effect of IL-10 deficiency on IL-17 production. Untreated or anti-TNF-α Ab-
treated cells from IL-10-deficient mice (open bars) produce significantly more IL-17 than wild-
type counterparts (closed bars) when incubated with 2.5 µg Ab. No difference in IL-17 
production was observed when cultures contained anti-IL-17 antibody. Values indicate 
means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05. 
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mice than infected, untreated mice (Fig. 19A). Sera from infected mice treated with 
both anti-TNF-α and anti-IL-17 antibodies possessed a one-fold greater titer of 
borreliacidal antibodies than infected mice that received antibodies to IL-17 alone 
(Fig. 19A).  
 
 
 
 
By contrast, serum from infected, anti-TNF-α antibody-treated, IL-10-deficient mice 
had a three-fold less borreliacidal antibody titer than serum from infected, 
untreated IL-10-deficient mice (Fig. 19B). In addition, the sera from infected IL-10-
deficient mice treated with both anti-IL-17 and anti-TNF-α antibodies exhibited a 
two-fold higher borreliacidal antibody titer than the sera from mice treated with anti-
IL-17 antibody alone (Fig. 19B).  
Figure 19. Borreliacidal antibody production. Borreliacidal antibody titers from serum of 
wild-type (A) and IL-10-deficient (B) mice. Mice were infected with B. burgdorferi and were 
untreated or treated with anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and anti-IL-17 Abs 
for 4 days following infection. Sera were collected on day 8 after infection. Groups consisted 
of 4-5 mice each.  
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CHAPTER 4: DISCUSSION                             
This thesis describes the effect of TNF-α on IL-17 production during the immune 
response to B. burgdorferi infection in wild-type and IL-10 deficient C57BL/6 mice. 
The central hypothesis was that TNF-α will regulate the immune response to B. 
burgdorferi infection by decreasing IL-17 production. To analyze the effect of TNF-
α on IL-17 in a mouse infection model of Lyme arthritis, B. burgdorferi-infected 
mice were treated with anti-TNF-α antibodies to quantify in vitro IL-17 production, 
paw swelling, and borreliacidal antibody production. Additionally, isolated spleen 
cells from infected mice were treated in vitro with anti-TNF-α antibodies to measure 
the amount of IL-17 produced. The following two specific aims were tested: (1) 
determine the effect of TNF-α on IL-17 in the immune response to B. burgdorferi 
infection and (2) determine the effects of TNF-α on the borreliacidal antibody 
response following infection with B. burgdorferi.   
  
During the immune response to B. burgdorferi, macrophages and neutrophils are 
activated to produce inflammatory cytokines including IL-1β, TNF-α, and IL-6 that, 
in turn, activate an inflammatory cascade with an aim to kill the pathogen.  This 
interaction further yields production of IL-12 that is necessary for survival of Th1 
cells and IL-6 that is needed for Th17 cells. T cells then continue to perpetuate this 
positive feedback loop by releasing TNF-α, IL-17, and other cytokines. Research 
suggests that IL-17 regulates inflammation by acting on TNF-α (Fossiez et al., 
1996; Jovanovic et al., 1998; Zwerina et al., 2012). While these studies indicate 
that IL-17 affects TNF-α production, other research demonstrates that, actually, 
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TNF-α mediates IL-17 production (Iwamoto et al., 2007, Chen et al., 2001). What 
is known is that both TNF-α (Yssel et al., 1991) and IL-17 (Codolo et al., 2008, 
2013) are produced in response to B. burgdorferi infection in humans, and that IL-
17 contributes to Lyme arthritis development in mice (Burchill et al. 2003; Hansen 
et al. 2013). Surprisingly, treatment with anti-TNF-α antibodies to IFN-γ-deficient, 
Borrelia-vaccinated and -infected mice aggravated arthritis in mice 
(Christopherson et al., 2003). Therefore, we set out to determine if TNF-α would 
have same protective role in a standard infection model of Lyme arthritis and, 
importantly, if TNF-α would induce IL-17 production, leading to inflammation.  
 
In this study, we show that TNF-α plays a protective role during inflammation 
elicited by B. burgdorferi infection in C57BL/6 mice. Additionally, TNF-α affects IL-
17 production. These findings were evident when anti-TNF-α antibodies were 
injected into B. burgdorferi-infected wild-type mice for four consecutive days, and 
the mice presented with increased (although not significant statistically) swelling 
of the hind paws compared to untreated control mice (data not shown and Fig. 1). 
Furthermore, IL-17 production significantly increased in infected mice when they 
were treated with anti-TNF-α antibodies (Fig. 3). Additionally, greater amounts of 
IL-17 were measured from spleen cells that were obtained from infected, wild-type 
mice and that were treated in vitro with anti-TNF-α antibodies (Fig. 12). Importantly, 
compared to anti-TNF-α antibody-treated mice, both paw swelling and IL-17 
production were reduced when mice were additionally injected with anti-IL-17 
antibodies (Figs. 1 and 3). 
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These results that TNF-α protects against inflammation early after infection with B. 
burgdorferi support and extend the findings by Christopherson, et al. (2003). These 
researchers showed that Borrelia-vaccinated and -infected, IFN-γ-deficient, 
C57BL/6 mice treated with anti-TNF-α antibodies had increased paw swelling and 
severe arthritis. They also showed that paws from infected mice injected with 
recombinant TNF-α displayed decreased swelling and amelioration of arthritis 
(Christopherson et al., 2003). It is important to note that they obtained these results 
using the Borrelia-vaccination and -challenge model arthritis. In contrast, we used 
a standard infection model in C57BL/6 mice, which are well known to be resistant 
to developing Lyme arthritis. It is possible that one mechanism for this resistance 
is that TNF-α is produced after infection with B. burgdorferi and acts in part to 
reduce the IL-17 response. In addition, we saw an even greater effect of anti-TNF-
α antibody in promoting paw inflammation in IL-10-deficient mice. This is important 
because this mouse model has recently been suggested as a good model for the 
study of Lyme disease in humans (Sonderegger et al., 2012). Furthermore, 
Yrjänainen et al. (2007) demonstrated that treatment of infected mice with anti-
TNF-α antibodies and ceftriaxone actually increases the number of spirochetes in 
tissues. It is reasonable to assume that the increased bacterial load could lead to 
increased paw swelling and arthritis development. In addition, although we did not 
assess pathology here, the increased paw swelling and IL-17 levels in IL-10-
deficient mice, compared to wild-type mice, are consistent with moderate-to-
severe arthritis (Hansen et al., 2013). 
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What role does TNF-α play during inflammation? The protective role of TNF-α is 
not uncommon during infections elicited by pathogens, including B. burgdorferi 
(Christopherson et al., 2003), Mycobacterium bovis (Olleros et al., 2002) and 
Listeria (Grivennikov et al., 2005). In studies of RA, some patients that receive anti-
TNF-α therapy actually have increased Th17 cytokines (Chen et al., 2011). 
Similarly, certain patients that are treated for RA with TNF-α inhibitors may develop 
psoriasis skin lesions (Kary et al., 2006, De Gannes et al., 2007). Ma et al. (2010) 
analyzed the mechanism of action in development of psoriasis with treatment of 
TNF-α antagonists in an animal model of disease, and found that inhibition of TNF-
α increased IL-17 and interleukin-22 compared to a control treatment. Therefore, 
production of the pro-inflammatory cytokine TNF-α may provide a counter-intuitive 
role in diseases such as early Lyme borreliosis. It is possible that early production 
of TNF-α acts to limit the growth and spread of B. burgdorferi for a period of time, 
with the result being that the IL-17 response does not develop immediately. 
 
However, in contrast, other studies showed a decrease in the amount of IL-17 
following inhibition of TNF-α. Moran et al. (2009) reported that treatment with anti-
TNF-α antibodies significantly decreased production of IL-17 in RA patients 
classified as responders to TNF-α therapy. Chen et al. (2011) also reported a 
decrease in Th17 cytokines from responders treated with TNF-α inhibitors. 
Likewise, administration of etanercept (a soluble TNF-α receptor approved for 
treatment of RA) to psoriasis patients decreased the number of Th17 cells (Zaba 
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et al., 2007). Furthermore, uveitis treatment with anti-TNF-α antibodies affected 
CD4 T cells to significantly decrease IL-17 production (Sugita et al., 2012). 
Therefore, the effect of TNF-α on IL-17 production likely varies, depending on the 
disease model studied. It is possible that infection-induced disease may cause a 
different effect on IL-17 than that which is seen during autoimmune diseases. 
 
The varying effect of TNF-α on IL-17 production can be extended to include 
regulatory T (Treg) cells, which are widely known to be related in development to 
Th17 cells. While treatment with anti-TNF-α antibody in an animal model of 
psoriasis lowered the frequency of Treg cells (Ma et al., 2010) in humans with RA, 
it was also shown that treatment with adalimumab (a monoclonal TNF-α antibody 
approved for treatment of RA) increased Treg cells by decreasing Th17 cells 
through inhibition of IL-6 (McGovern et al., 2012). However, the Treg cell increase 
was not observed in patients taking etanercept. The correlation between Treg 
populations in adalimumab- and etanercept-treated groups was also assessed in 
the risk for development of tuberculosis. Patients treated with adalimumab showed 
7-17 times greater risk of developing tuberculosis infection than patients treated 
with etanercept, which the authors suggest is possible reactivation of latent 
infection (Tubach et al., 2009). Since Lyme disease is caused by a bacterium that 
also may cause chronic disease, use of anti-TNF-α antibodies needs to be treated 
with caution.    
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In our study, eight days after B. burgdorferi-infection, no differences in relative paw 
swelling were measured between untreated wild-type mice and mice injected with 
anti-IL-17 antibodies for four consecutive days (Fig. 1). These results seem to 
suggest that IL-17 is not involved in the immune response during B. burgdorferi 
infection, contrary to numerous findings (Burchill et al. 2003; Nardelli, et al. 2004, 
2005, 2008; Kotloski et al. 2008; Hansen et al., 2013). After 18 hours of incubation, 
there was an unexpected increase in IL-17 production from spleen cells collected 
from infected, anti-IL-17 antibody treated mice (Fig. 3). However, as expected, 24 
hours after incubation, cells harvested from infected, anti-IL-17 antibody-treated 
mice produced significantly less IL-17 than cells from infected, untreated controls 
(Figs. 6). In addition, in vitro treatments with anti-IL-17 antibody slightly decreased 
IL-17 production by wild-type cells when compared to the amounts of IL-17 from 
spleen cells harvested from infected but untreated mice (Figs. 14  and 15). A 
possible explanation why we did not see a decrease in paw swelling with anti-IL-
17 antibody treatment is that we treated mice for four days and assessed swelling 
at only two time points, before infection and 8 days after infection. Other studies 
treated infected wild-type C57BL/6 mice with anti-IL-17 antibodies for 7 days and 
measured paw swelling every other day. For example, in a previous study (Hansen 
et al., 2013), treatment with anti-IL-17 antibodies was administered for 7 days. 
Statistically less swelling was shown in B. burgdorferi-infected, anti-IL-17 antibody-
treated mice than infected, untreated wild-type mice at day 6 after infection. 
However, as we show here, this difference was not seen at day 8 (Hansen et al. 
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2013). Therefore, it is likely that IL-17 is involved in immune response during B. 
burgdorferi infection, even though no significance is demonstrated in this study. 
  
How does IL-17 play a role in joint destruction? Under normal conditions, bone 
structure depends on the continuous balance of osteoblasts and osteoclasts for 
bone remodeling and resorption. During arthritic conditions, osteoclastogenesis is 
increased, while production of osteoblasts is decreased, leading to bone erosion. 
IL-17 has been implicated in promoting osteoclastogenesis (Zwerina et al., 2012) 
through increased production of IL-1β. Additionally, IL-17 is a powerful inducer of 
inflammatory cell migration and invasion of the joint tissue (Hot et al., 2012). 
Furthermore, IL-17 acts to stop collagen synthesis of bones and synovial tissue, 
along with inhibiting prostaglandin synthesis by cartilage cells (Chaubad et al., 
2001). All of these studies point to the direct involvement of IL-17 in bone 
destruction in arthritis. The increase in IL-17 following administration of antibodies 
to TNF-α after B. burgdorferi infection provide a possible mechanism for the 
protection given by TNF-α. While stimulation of PBMCs from healthy patients with 
TNF-α did not stimulate production of IL-17 (Ziolkowska et al., 2000), we found 
that generally, anti-TNF-α antibody treatment increases IL-17 production in wild-
type mice (Figs. 3, 4, and 12). Overall, the amounts of IL-17 in three different 
treatment groups of infected mice were higher for an incubation period of 18 hours 
than 24 hours (Figs. 3, 4, 6, and 7). Interestingly, treatment of mice with both anti-
IL-17 and anti-TNF-α antibodies induced undetectable levels of IL-17 in stimulated 
wild-type cells (Fig. 7). 
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What contributes to this decrease? Literature suggests that TNF-α and IL-17 can 
work synergistically. For instance, addition of both TNF-α and IL-17 increased IL-
1β and IL-6 (Katz et al., 2001) production. It also has been demonstrated that both 
IL-17 (Shalom-Barak et al., 1998) and TNF-α (Englaro et al., 1999) mediate 
inflammation through the NF-κB pathway which, in turn, produces more 
inflammatory cytokines, including IL-6 and IL-8 (Katz et al., 2001), that form a 
positive feedback loop. Similarly, the NF-κB pathway is activated during 
osteoclastogenesis and bone resorption (Zwerina et al., 2012). Considering that 
Th17 cells produce both IL-17 and TNF-α, with TNF-α possibly causing positive 
feedback on Th17 cell production, it seems reasonable that inhibition of both of 
them may lower IL-17 levels considerably. It is important to emphasize that our 
study included a treatment group with both anti-IL-17 and anti-TNF-α antibodies, 
and the expected results were a further decrease in IL-17 than what would be seen 
with anti-IL-17 antibody treatment alone. This usually did not occur. This possibly 
could be due to an already strong neutralizing effect of the anti-IL-17 antibody. In 
support of this, using 2.5 µg of anti-IL-17 antibody has been shown to be effective 
in preventing arthritis after infection with B. burgdorferi (Burchill et al. 2003; Nardelli 
et al. 2004; Hansen et al. 2013). However, at what stage of disease TNF-α takes 
on the protective role in B. burgdorferi infection remains to be determined.  
 
Susceptibility to Lyme arthritis differs by mouse strains. Wild-type C57BL/6 mice 
are arthritis-resistant, and C3H/HeJ mice are arthritis-susceptible. However, 
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Brown et al. (1999) demonstrated that C57BL/6 mice that are deficient in the anti-
inflammatory cytokine IL-10 are arthritis-susceptible. This study also showed that 
macrophages derived from wild-type C57BL/6 mice produce more IL-10 than do 
C3H-derived macrophages in response to B. burgdorferi (Brown et al., 1999). 
Furthermore, in vitro stimulation of PMBCs from healthy rhesus monkeys and 
humans with B. burgdorferi resulted in production of IL-10 and a decrease in IL-12 
(Giambartolomei et al., 1998). The higher production of IL-10 in arthritis-resistant 
mice provides a possible mechanism for the bacteria to survive in the host long 
enough to cause disease. Our results indicate more ankle swelling in infected, IL-
10-deficient C57BL/6 mice compared to infected wild-type mice (Figs. 1 and 2). 
These results were also reported in a previous study (Hansen et al., 2013) and by 
others (Brown et al., 1999; Crandall et al., 2006). It has been shown that reduced 
levels of IL-10 substantially contribute to arthritis susceptibility in mice otherwise 
known to be arthritis-resistant by increased production of IL-17 (Hansen et al., 
2013).  
 
Overall, in our study, infected IL-10-deficient mice treated in vivo with anti-TNF-α 
antibodies produced more IL-17 than untreated wild-type mice when cells were 
incubated for 18 hours (Fig. 5). In vitro treatment of spleen cells with 2.5 µg and 
10 µg of anti-TNF-α also caused increases in IL-17 production in between IL-10-
deficient and wild-type mice (Fig. 18 and data not shown). However, these 
differences were not seen at concentrations of 5 µg, or in anti-IL-17 or dual-
antibody treated groups (Fig. 18 and data not shown). It is reassuring that our in 
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vitro data shows consistent statistical significances in IL-17 production of IL-10-
deficient mice between untreated and anti-IL-17 antibody treated groups at all 
three concentrations (Figs. 15, 16, and 17). These results support in vivo findings 
in a previous study (Hansen et al., 2013) and implicate IL-17 in development of 
Lyme arthritis. In another study, bone-marrow derived macrophages cultured with 
B. burgdorferi and treated with anti-IL-10 antibodies produced increased levels of 
pro-inflammatory cytokines, while addition of recombinant IL-10 decreased IFN-γ, 
IL-6 and TNF-α (Gautam et al., 2012). Therefore, it is likely that IL-10 controls 
multiple inflammatory pathways implicated in development of Lyme arthritis. 
 
How are IL-10 and TNF-α regulated in Lyme arthritis? Literature suggests that IL-
10 and TNF-α have an inverse relationship in disease. For example, treatment of 
synovial fluid mononuclear cells with anti-IL-10 antibodies increased in vitro 
production of TNF-α, while addition of recombinant IL-10 to the cells decreased 
the amount of TNF-α (Yin et al., 1997). Additionally, when normal blood was 
incubated with B. burgdorferi, production of IL-10 was increased, whereas TNF-α 
was decreased (Diterich et al., 2001). Furthermore, addition of recombinant IL-10 
to cultures of a human monocytic cell line incubated with spirochetes decreased 
production of TNF-α (Murthy et al., 2000). However, treatment of these cells with 
anti-IL-10 antibodies did not lower the amount of TNF-α produced (Murthy et al., 
2000). IL-10 is known to down-regulate the NF-κB pathway (Lentsch et al., 1997), 
while TNF-α up-regulates the NF-κB pathway (Englaro et al., 1999). Macrophages 
stimulated with B. burgdorferi showed an increase in NF-κB after stimulation with 
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B. burgdorferi, but when recombinant IL-10 was added, this response was lowered 
(Gautam et al., 2011). These studies indicate that IL-10 can regulate the influence 
of TNF-α during B. burgdorferi infection and, possibly, Lyme arthritis. We showed 
that in the absence of IL-10, blocking TNF-α, more often than not, had little effect 
on the production of IL-17. By contrast, in the presence of IL-10, blocking TNF-α 
occasionally increased the production of IL-17. Therefore, IL-10 may regulate the 
interaction of TNF-α and IL-17 following B. burgdorferi infection. We also showed 
that a lack of IL-10 in B. burgdorferi-infected mice causes an extremely strong IL-
17 response (Hansen et al., 2013). This may explain why blocking TNF-α in vivo 
(Fig. 10 and 11) or in vitro (Fig. 15, 16, and 17) did not consistently result in a 
change in IL-17 production by cells of infected, IL-10-deficient mice. 
 
Previously, it was shown that recombinant TNF-α can increase the borreliacidal 
antibody response in B. burgdorferi-vaccinated and -infected, IFN-γ-deficient mice 
(Christopherson et al., 2003). Furthermore, injection of anti-TNF-α antibodies to 
these mice significantly reduced borreliacidal antibody titers (Christopherson et al., 
2003). To determine if TNF-α affected the borreliacidal antibody response in wild-
type and IL-10-deficient mice infected with B. burgdorferi, serum from was 
collected and analyzed by a borreliacidal antibody assay. Contrary to the results 
of Christopherson, et al. (2003), the borreliacidal antibody response in infected 
wild-type mice was increased when these mice were treated with anti-TNF-α 
antibody. However, this increase was only one-fold different (Fig. 19A), and 
therefore was likely not significant. Administration of anti-TNF-α antibodies also 
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caused a one-fold increase in the borreliacidal antibody titers observed in infected 
wild-type mice treated with anti-IL-17 antibodies (Fig. 19A). These conflicting 
results may be due to the disease model used. Borrelia-vaccinated and -infected, 
IFN-γ-deficient C57BL/6 mice exhibit severe arthritis, while infected wild-type 
C57BL/6 mice exhibit mild inflammation. To support this, we showed that infected 
IL-10-deficient C57BL/6 mice (which are moderately-to-severely arthritic) showed 
a three-fold decrease in borreliacidal antibody titers (10240 to 1280) due to anti-
TNF-α antibody treatment (Fig. 19B). These results are similar to those of 
Christopherson et al. (2003), which showed decreased borreliacidal titers in mice 
infected with B. burgdorferi and treated with anti-TNF-α. Infected IL-10-deficient 
mice also showed a five-fold decrease (10240 to 320) due to anti-IL-17 antibody 
treatment (Fig. 19B), indicating that TNF-α and IL-17 each promote borreliacidal 
activity in IL-10-deficient mice. Additionally, we showed a similar titer for both 
infected but untreated wild-type and IL-10-deficient mice (Figs. 19A and 19B). 
Contrary to our studies, Brown et al. (1999) showed differences between 
borreliacidal titers in wild-type and IL-10-deficient C57BL/6 mice. However, it is 
important to note that these borreliacidal antibodies were analyzed four weeks 
after infection, while we quantified borreliacidal titers eight days after infection. It is 
highly likely that extended infection could alter the borreliacidal response and 
magnify differences between the two strains of mice.  
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CHAPTER 5: CONCLUSION AND FUTURE DIRECTIONS     
In conclusion, this thesis addressed two specific aims. Specific Aim 1 was to 
determine the effect of TNF-α on IL-17 in the immune response to B. burgdorferi 
infection. The working hypothesis of this specific aim was that TNF-α would 
decrease IL-17 production following B. burgdorferi infection. This hypothesis was 
partially supported by the data presented in this study. Briefly, it was shown that 
anti-TNF-α antibody treatment of B. burgdorferi-infected wild-type mice increased 
the IL-17 levels produced by spleen cells. By contrast, this effect was not 
consistently observed in IL-10-deficient mice, although we did show that 
unstimulated cells from infected, anti-TNF-α antibody-treated mice produced a 
relatively large amount of IL-17. Overall, these data indicate that TNF-α may play 
a protective role during B. burgdorferi infection in C57BL/6 mice by suppressing 
the production of IL-17.  
 
Specific Aim 2 addressed effects of TNF-α and IL-17 on the borreliacidal antibody 
response following infection with B. burgdorferi. The working hypothesis for this 
aim stated that anti-TNF-α treatment of B. burgdorferi-infected mice would inhibit 
borreliacidal antibody production, which would be reversed by also blocking IL-17. 
This hypothesis was also partially supported. Our data indicated that in infected 
wild-type mice, treatment with anti-TNF-α antibody had a minimal effect on 
increasing borreliacidal antibody titers. Additionally treating these mice with anti-
IL-17 antibodies minimally reduced this production relative to anti-TNF-α antibody-
treated mice, but minimally increased production compared to anti-IL-17 antibody-
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treated mice. However, in infected IL-10-deficient mice, treatment with anti-TNF-α 
antibodies did, indeed, reduce borreliacidal antibody titers. However, addition 
blockage of IL-17 further reduced these titers, rather than reversed the effects of 
anti-TNF-α antibody treatment.   
 
These conclusions additionally support the literature that suggests that TNF-α 
plays a protective role in B. burgdorferi infection. We provide a potential 
mechanism for this protection: inhibiting the production of IL-17, which has been 
shown to contribute to the development of Lyme arthritis in mouse models of 
disease (Burchill, et al. 2003; Nardelli et al. 2004, 2005, 2008; Hansen et al. 2013). 
However, other findings provide a warning about the use of anti-TNF-α therapy in 
treating Lyme arthritis because these treatments (1) may stimulate persisting 
infection (Yrjänainen et al., 2007), (2) increase IL-17 levels (Chen et al., 2011) in 
other systems, and (3) affect production of Treg cells (Ma et al., 2010; McGovern 
et al., 2012) which may or may not be desirable in the context of infection-mediated 
inflammation. 
 
In conclusion, we show that TNF-α can play a protective role during B. burgdorferi 
infection and provide support that this protection involves suppressing IL-17 
production. Future studies that require investigation include examining the effect 
of IL-17 on TNF-α production during B. burgdorferi infection. Additionally, the 
relationship between IL-17 and TNF-α will be studied in the early and later stages 
of B. burgdorferi infection, since the effects of TNF-α vary based on the disease 
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system, as well as the phase of disease at which it is considered (Grivennikov et 
al., 2005).  
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